Hyderabad Policy Conclave – The Indian ERA

Foreword

India has made remarkable progress in expanding access to healthcare and strengthening its pharmaceutical capabilities. Today, our country is recognised globally as one of the largest manufacturers of high-quality generic medicines, supplying affordable medicines to millions of people across the world. Yet, within our own healthcare system, many patients continue to struggle with the high cost of medicines, while misconceptions and trust deficits continue to influence the acceptance and use of generic medicines.

This paradox reminds us that good policy alone does not guarantee meaningful outcomes. The true measure of public policy lies in its implementation — how effectively it reaches people, earns their confidence, and improves their lives. Bridging the gap between policy intent and practice requires continuous dialogue, evidence-based learning, institutional collaboration, and a shared commitment to solving implementation challenges.

It was with this belief that Vaaradhi Trust partnered with the School of Public Policy and Governance (SPPG), Tata Institute of Social Sciences (TISS), Hyderabad, to convene the Generic Medicines & Public Health Governance Track at the Hyderabad Policy Conclave – The Indian ERA. The conclave provided a national platform where policymakers, regulators, healthcare professionals, pharmaceutical industry leaders, academics, civil society organisations, and public health practitioners came together to examine one fundamental question: how can India strengthen trust in generic medicines while ensuring that affordable healthcare reaches every citizen?

The discussions moved beyond theoretical debates to focus on the realities of implementation. The two thematic sessions — Trust in Generic Medicines – Built or Broken? and Jan Aushadhi on the Ground – What Worked and What Did Not — brought together diverse perspectives from across the healthcare ecosystem. Participants examined behavioural barriers, regulatory capacity, quality assurance, market sustainability, prescribing practices, supply chain challenges, public awareness, and institutional accountability.

Trust cannot be mandated; it must be earned. Trust is built through transparent institutions, consistent quality standards, credible regulation, responsible prescribing, informed patients, and sustained public engagement.

The insights documented in this report represent the collective wisdom of distinguished experts and practitioners who shared their experience from policy, clinical practice, pharmaceutical manufacturing, retail pharmacy, public administration, patient advocacy, and community health. These deliberations have informed a set of policy recommendations that seek to strengthen implementation systems, improve public trust, and enhance access to quality-assured generic medicines.

At Vaaradhi Trust, we believe that affordable healthcare is not simply an economic objective — it is a matter of equity, dignity, and social justice. Through our Generics for All initiative, we remain committed to promoting awareness, accessibility, and trust in quality generic medicines while working collaboratively with governments, academic institutions, healthcare professionals, industry, and communities.

Vaaradhi Trust extends its sincere appreciation to the School of Public Policy and Governance, TISS Hyderabad, for providing a distinguished academic platform for these important deliberations, and to all panellists, moderators, policymakers, regulators, healthcare professionals, industry leaders, researchers, civil society organisations, and participants whose contributions shaped this report.

If the ideas presented here contribute, even in a small way, to building greater trust in generic medicines and improving access to quality healthcare, the objectives of this conclave will have been well served. Together, let us continue to build a healthcare system that is affordable, accessible, trusted, and centred on the well-being of every citizen.

Executive Summary

The Hyderabad Policy Conclave – The Indian ERA, held from 27–29 April 2026 at MCRHRD Institute, Hyderabad, was conceived as a national platform to strengthen implementation excellence by bridging the gap between policy intent and real-world practice. Anchored by the School of Public Policy and Governance (SPPG), Tata Institute of Social Sciences (TISS), Hyderabad, and co-hosted by Vaaradhi Trust, the conclave brought together policymakers, regulators, healthcare professionals, industry leaders, researchers, academicians, civil society organisations, and public health practitioners.

As part of the conclave, Vaaradhi Trust convened the Generic Medicines & Public Health Governance Track under its Generics for All initiative. This thematic track recognised that while India is globally acknowledged as one of the world’s leading manufacturers of quality generic medicines, domestic utilisation continues to be constrained by trust deficits, behavioural barriers, implementation challenges, and gaps between policy design and practice.

The first session, Trust in Generic Medicines – Built or Broken?, examined behavioural, institutional, and regulatory factors influencing public confidence. Discussions highlighted that the principal challenge extends beyond trust in the medicines themselves to trust in the broader healthcare ecosystem — misconceptions regarding quality, limited public understanding of bioequivalence, inconsistent prescribing, weak regulatory visibility, and inadequate awareness.

The second session, Jan Aushadhi on the Ground – What Worked and What Did Not, assessed the Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP). Participants acknowledged significant expansion of access, while identifying delayed government payments, commercially unsustainable pricing, regulatory capacity constraints, limited awareness, uneven prescribing, supply-chain issues, and behavioural barriers.

Across both sessions, a consistent message emerged: trust is the foundation of affordable healthcare, and it cannot be established through policy directives alone. Drawing upon the deliberations, Vaaradhi Trust developed two policy briefs that translate discussion into action — calling for stronger regulatory institutions, manufacturing quality assurance, public awareness, generic prescribing, pharmacist-led counselling, timely procurement and payment, technology-enabled supply chains, implementation research, and public–private collaboration.

This report documents the proceedings of the track and presents the collective insights, key findings, and policy recommendations that emerged. It is intended as a resource for policymakers, healthcare institutions, regulators, academia, industry, and civil society working towards a healthcare system that is affordable, accessible, quality-assured, and trusted by every citizen.

About the Hyderabad Policy Conclave

The Hyderabad Policy Conclave – The Indian ERA is a first-of-its-kind national platform dedicated to strengthening implementation excellence by bridging the gap between policy intent and real-world practice. Anchored by SPPG, TISS Hyderabad, it provides a multidisciplinary forum where policymakers, practitioners, researchers, regulators, industry leaders, academia, and civil society examine how public policies are implemented, identify systemic challenges, and develop practical solutions.

Held from 27–29 April 2026 at MCRHRD Institute, Hyderabad, the conclave recognised that while India has made significant progress in designing progressive policies, successful implementation often remains the defining challenge. Differences in institutional capacity, behavioural factors, public trust, market dynamics, and administrative systems frequently influence how policies translate into outcomes.

Unlike conventional conferences that focus primarily on policy formulation, the conclave adopts a problem-first and evidence-driven approach. Discussions are informed by implementation experiences from practitioners, government institutions, industry, researchers, and communities — examining not only what policies seek to achieve but also how they function in practice.

Vaaradhi Trust co-hosted the Generic Medicines & Public Health Governance Track under its Generics for All initiative. The track examined affordable healthcare, focusing on trust in generic medicines, wider adoption, and the effectiveness of PMBJP. At its core, the conclave reflects a simple principle: effective public policy is measured not only by the quality of its design, but by the quality of its implementation and the impact it creates for citizens.

About the Organisers

Generics for All

Generics for All (GFA) is Vaaradhi Trust’s flagship public health programme, dedicated to improving the affordability, accessibility, and acceptance of quality-assured generic medicines. It is founded on the belief that no individual should be denied essential medicines because of financial constraints or misinformation.

Why Generic Medicines Matter

Access to affordable medicines is one of the cornerstones of an equitable healthcare system. In India, expenditure on medicines constitutes a substantial proportion of out-of-pocket healthcare spending, making affordability a critical determinant of access.

India is internationally recognised as the “Pharmacy of the World.” Indian pharmaceutical companies supply high-quality, affordable medicines globally. Despite this leadership, domestic adoption has not reached its full potential. Misconceptions regarding quality, efficacy, and safety continue to influence prescribing, dispensing, and patient preference.

Generic medicines contain the same active ingredients and are intended to deliver the same therapeutic outcomes as branded counterparts, at significantly lower prices. Wider adoption can reduce healthcare expenditure, improve treatment adherence, and expand access — particularly for economically vulnerable populations. Affordable medicines are therefore not only a healthcare issue but a matter of social equity and financial protection.

The Government of India has introduced important initiatives, including PMBJP, expansion of Jan Aushadhi Kendras, and measures encouraging prescription by generic name. Their long-term success depends not only on policy design but on implementation, stakeholder confidence, and public trust. As India continues its journey towards Universal Health Coverage, building trust in generic medicines is an essential component of strengthening public health systems and reducing financial hardship.

Objectives of the Conclave

The track was conceived to facilitate evidence-informed dialogue on improving access to affordable, quality-assured medicines through stronger implementation systems and greater public trust. The principal objectives were to:

1. 01

   Strengthen trust in generic medicines

   Examine behavioural, institutional, regulatory, and market-related factors, and identify practical strategies for strengthening public confidence in quality, safety, efficacy, and therapeutic equivalence.

2. 02

   Bridge the gap between policy and practice

   Analyse how existing policies and programmes are implemented on the ground, identify gaps, and generate recommendations to improve delivery systems and outcomes.

3. 03

   Promote evidence-informed policy dialogue

   Provide a neutral platform that integrates policy perspectives with field experience, implementation evidence, and practitioner insight.

4. 04

   Examine the Jan Aushadhi programme

   Assess PMBJP achievements, operational challenges, market sustainability, accessibility, supply chains, and integration within the healthcare system.

5. 05

   Understand behavioural and institutional barriers

   Explore how prescribing, patient perception, pharmacy practice, regulation, quality assurance, and public awareness shape utilisation.

6. 06

   Encourage multi-stakeholder collaboration

   Bring government, regulators, academia, healthcare, industry, pharmacy networks, civil society, and patient groups into shared problem-solving.

7. 07

   Develop actionable policy recommendations

   Translate deliberations into practical, evidence-based recommendations that strengthen implementation, trust, and access.

8. 08

   Contribute to India’s implementation learning ecosystem

   Generate knowledge products that feed the Hyderabad Declaration, National Implementation Compendium, and Digital Knowledge Repository.

9. 09

   Advance affordable and equitable healthcare

   Contribute to a system in which affordability, accessibility, quality assurance, and public trust ensure medicines without financial hardship.

Conclave Framework

Convened by Vaaradhi Trust under Generics for All and co-hosted by SPPG, TISS Hyderabad, the track adopted a structured, evidence-informed framework. Unlike conventional conferences focused on formulation or technical presentations, it used a problem-first approach — examining implementation realities through the experience of practitioners, policymakers, regulators, healthcare professionals, industry, researchers, and civil society.

Guiding principles

Thematic structure

Deliberations were conducted through moderated panel discussions. Each session was supported by rapporteur documentation. These were synthesised into two policy briefs: Trust in Generic Medicines: Behaviour, Perceptions, and Practice and Jan Aushadhi on the Ground: What Worked and What Did Not.

Participants and Stakeholders

The track brought together stakeholders from government, healthcare, academia, industry, civil society, and public policy. Recognising that the challenges around generic medicines extend beyond any single institution, the conclave adopted a multi-stakeholder approach that combined policy experience, clinical expertise, regulatory understanding, market insight, patient perspective, and implementation knowledge.

• Government and former senior civil servants
• Public health institutions and teaching hospitals
• Medical professionals and specialist clinicians
• Pharmaceutical manufacturers and industry leaders
• Pharmacy retail and distribution networks
• Patient advocacy organisations
• Public health and civil society organisations
• Academic and policy institutions
• Researchers and implementation practitioners

Proceedings – Session I

Trust in Generic Medicines – Built or Broken?

The inaugural session focused on one of the most significant challenges confronting India’s affordable healthcare agenda — building public trust in generic medicines. Although India is recognised globally as one of the largest producers and exporters of generics, domestic adoption continues to be influenced by concerns relating to quality, efficacy, safety, prescribing behaviour, and public perception.

Rather than viewing trust solely as a function of medicine quality, the discussion recognised that trust is shaped by the credibility of the broader healthcare ecosystem: regulatory oversight, prescribing, manufacturing standards, communication, and institutional accountability.

Understanding the trust deficit

A recurring theme was that the principal challenge is not trust in the medicine molecule itself, but trust in the healthcare ecosystem surrounding it. The lower price of generics is frequently interpreted as inferior quality — reinforced by limited public understanding of manufacturing standards, bioequivalence, regulatory approvals, and quality assurance. Strengthening confidence requires improving both the reality and the visibility of quality assurance.

Perspectives from key stakeholders

Doctors. Patients generally rely on their treating physician. While many clinicians recognise the value of generics, hesitation persists due to concerns about manufacturing consistency, quality assurance, and patient perception. Even when doctors reassure patients, pre-existing misconceptions often continue to influence behaviour.

Patients. Common beliefs included that generics are less effective, act more slowly, use inferior ingredients, or are less reliable because they cost less. Changes in colour, packaging, or tablet appearance are frequently read as poor quality. Medicines provided free through government programmes are sometimes viewed with suspicion — reflecting broader confidence in systems, not the molecule alone.

Pharmacies. Purchasing is often driven by patient confidence and physician recommendation rather than objective information on therapeutic equivalence. Brand recognition continues to dominate. Although generics generally offer higher commercial margins, those benefits are not always translated into lower consumer prices — highlighting the need for market transparency and accountability.

Regulation, policy, and markets

Participants emphasised visible, credible regulatory systems; consistent enforcement; and institutional transparency. PMBJP has substantially improved access, but expanding availability alone is insufficient without continued investment in regulation, quality assurance, credibility, and awareness. Information asymmetry continues to distort pharmaceutical markets. Bioequivalence remains poorly understood outside specialist circles and should be communicated in accessible language.

Key takeaways

Trust cannot be established solely through legislation. It must be built through transparent institutions, credible regulation, consistent product quality, informed professionals, responsible industry practice, and sustained public engagement. Government hospitals should serve as visible champions of generic medicines through consistent prescribing, dispensing, and patient education. These insights informed the policy brief Trust in Generic Medicines: Behaviour, Perceptions, and Practice.

Proceedings – Session II

Jan Aushadhi on the Ground – What Worked and What Did Not

The second session evaluated PMBJP from the perspective of policy implementation, healthcare delivery, market sustainability, and public access. Improving access requires more than expanding the number of Jan Aushadhi Kendras. Sustainable implementation depends on reliable supply chains, financially viable procurement, effective regulation, informed prescribing, public awareness, and coordinated institutional support.

Setting the context

Participants noted that Telangana records one of the highest per capita healthcare expenditures in the country — illustrating that high costs are not always explained by shortages in supply. In healthcare, information asymmetry, trust, and prescribing behaviour play a central role. A single episode of illness can impose severe financial hardship, reinforcing the importance of affordable, quality-assured medicines.

Achievements and sustainability

PMBJP has increased the availability of quality-assured generics through a growing network of Kendras and has demonstrated that affordability can improve without compromising quality. For many people managing chronic illness, it has reduced the financial burden of treatment. Long-term impact, however, depends on consistent availability, financial sustainability, and public confidence.

Although India possesses one of the world’s strongest generic industries, participation in government procurement remains constrained by commercial realities. Pricing is often perceived as below the cost of production for certain medicines. Delayed payments affect liquidity and reduce the sustainability of public procurement. Transparent, efficient, and financially sustainable procurement is essential.

Behaviour, regulation, and technology

Affordability alone does not guarantee utilisation. Many patients cannot distinguish branded from generic medicines, and “generic” is often incorrectly associated with lower quality. Limited generic prescribing reduces utilisation. Regulatory capacity — including shortages of skilled inspection personnel — affects public confidence. Qualified pharmacists available to counsel patients are an important institutional consideration.

Digital technologies and artificial intelligence can improve manufacturing efficiency, inventory, distribution, transparency, and public information. Technology should complement — not replace — strong institutions, effective regulation, and professional oversight. Health insurance providers can also encourage cost-effective prescribing where clinically appropriate.

Key takeaways

PMBJP has established a strong foundation. Long-term success depends on four interconnected priorities: institutional capacity, market sustainability, public trust, and behavioural change. These insights informed the policy brief Jan Aushadhi on the Ground: What Worked and What Did Not.

Cross-Cutting Themes

Across both sessions, challenges around generic medicines proved multidimensional and interconnected. Strengthening India’s ecosystem requires coordinated action across policy, regulation, healthcare delivery, industry, and public engagement.

1. Trust as the foundation of affordable healthcare

   The challenge is not the scientific validity of generic medicines, but the confidence that patients, professionals, and the public place in the systems that regulate, prescribe, dispense, and monitor them. Trust is multidimensional — manufacturing, regulation, prescribing, pharmacy, and communication must all hold.

2. Bridging the gap between policy and implementation

   India has important policies for affordable medicines, including generic prescribing and Jan Aushadhi. Outcomes still vary by institution and region. Effectiveness depends on capacity, operational efficiency, stakeholder engagement, and monitoring — not design alone.

3. Quality assurance and regulatory credibility

   Robust regulation, transparent quality assurance, consistent inspections, and timely enforcement are essential. Equally important is making these mechanisms visible so professionals and the public understand how quality is assured.

4. Behavioural change across the healthcare ecosystem

   Doctors, pharmacists, patients, institutions, and companies all shape medicine choices. Misconceptions about quality, efficacy, and safety persist. Behaviour-change strategies must combine scientific communication, education, training, and public awareness.

5. Patients at the centre of healthcare delivery

   Affordable medicines contribute little unless patients are confident, understand therapeutic value, and can access them when needed. Patient education, counselling, informed consent, and transparent communication are both a healthcare objective and a public-policy responsibility.

6. Market sustainability and access

   Affordability for patients must be balanced with commercial sustainability for manufacturers, distributors, and pharmacy networks. Procurement, pricing, delayed payments, and incentives all affect availability.

7. Strengthening institutional capacity

   Regulators, health departments, public hospitals, medical colleges, pharmacy networks, and providers play complementary roles. Staffing, expertise, training, infrastructure, and governance remain central to consistent implementation.

8. Collaboration across stakeholders

   No single institution can resolve these challenges. The conclave itself modelled the value of bringing policymakers, regulators, clinicians, industry, pharmacists, patient advocates, researchers, academia, and civil society into one room.

9. Evidence-based decision making

   Field studies, prescription audits, perception surveys, implementation assessments, and operational research should guide policy. The National Implementation Compendium and Digital Knowledge Repository are mechanisms for institutionalising that learning.

10. Technology as an enabler

    Digital systems can strengthen manufacturing, inventory, supply chains, regulation, and public information. Technology should reinforce — not substitute — institutions, professional judgement, and regulatory oversight.

11. An integrated generic medicines ecosystem

    Quality manufacturing, credible regulation, responsible prescribing, informed patients, accessible pharmacies, efficient supply chains, sustainable markets, and transparent governance must function as one system. Weakness in any component undermines confidence in all.

The future of affordable healthcare in India depends on systems that are trusted, transparent, responsive, and evidence-driven. Trust is earned through strong institutions, consistent quality, accountable governance, informed professionals, empowered patients, sustainable markets, and collaborative implementation.

Key Findings

Improving access to affordable medicines requires a comprehensive approach that addresses behavioural, institutional, regulatory, market, and implementation challenges simultaneously. The following findings emerged from the collective deliberations.

1. A strong manufacturing base, a domestic trust deficit

   India is a leading global manufacturer and exporter of generic medicines. That international credibility has not translated into equivalent public confidence at home. The principal challenge is trust, not availability.

2. Trust extends beyond the medicine

   Public confidence is shaped by manufacturing quality, regulatory oversight, prescribing, pharmacist interactions, institutional transparency, and prior healthcare experience. Trust-building must improve several components of the system at once.

3. Behavioural factors still drive medicine choices

   Patients often associate lower prices with inferior quality and rely primarily on physicians. Brand familiarity, misconceptions about efficacy, and limited awareness of therapeutic equivalence remain significant barriers.

4. Doctors are central to public confidence

   Healthcare professionals remain the most trusted source of information. Strengthening clinician awareness, evidence-based prescribing, and professional confidence in quality-assured generics is critical.

5. Public awareness remains inadequate

   Misconceptions about quality, safety, efficacy, manufacturing, and bioequivalence persist. Awareness should go beyond campaigns and improve health literacy through credible, evidence-based communication.

6. Regulatory credibility is fundamental

   Confidence in generics depends on confidence in regulators. Stronger implementation, transparency, visible quality assurance, and timely enforcement are essential.

7. Quality assurance must be more visible

   Quality systems exist, but their functioning is poorly understood outside regulatory and pharmaceutical circles. Better public communication on standards, inspections, bioequivalence, and monitoring would reduce misinformation.

8. Jan Aushadhi has improved access, with implementation gaps

   PMBJP has expanded access to affordable medicines. Procurement delays, supply-chain issues, limited awareness, inconsistent prescribing, and operational constraints still affect long-term performance.

9. Market sustainability needs greater attention

   Pricing, delayed government payments, procurement practice, and commercial viability influence manufacturer participation and medicine availability.

10. Pharmacists can do more in patient education

    Pharmacists are often the last point of contact before medicines reach patients. They can counsel, address misconceptions, and improve confidence in generics.

11. Technology can improve implementation

    Digital platforms, AI, inventory monitoring, and public information systems can improve transparency, efficiency, and availability — complementary to strong institutions, not a replacement for them.

12. Institutional capacity requires strengthening

    Regulatory agencies need better staffing, technical expertise, inspection capacity, and systems for timely monitoring and enforcement. This is a long-term investment in affordable healthcare.

13. Multi-stakeholder collaboration is essential

    Sustainable improvement requires government, regulators, providers, manufacturers, pharmacists, academia, patient organisations, insurers, and civil society working together on structured platforms.

14. Evidence should guide policy and implementation

    Research, prescription audits, perception studies, operational assessments, and policy evaluation should inform reforms that respond to ground realities.

15. Affordable healthcare requires a systems approach

    Quality manufacturing, credible regulation, responsible prescribing, informed patients, efficient supply chains, sustainable markets, awareness, accountability, and implementation excellence reinforce one another. Isolated interventions have limited impact.

India possesses both the scientific capability and the policy framework necessary to expand the use of quality-assured generic medicines. The principal challenge now lies in strengthening implementation through coordinated action, transparent governance, evidence-based policymaking, strong institutions, and sustained public engagement.

Consolidated Policy Recommendations

While India possesses a strong pharmaceutical manufacturing base and a well-defined policy framework, implementation challenges continue to limit the full potential of affordable-medicine initiatives. The following recommendations are organised into nine strategic pillars for government departments, regulators, healthcare institutions, and development partners.

These recommendations provide an integrated roadmap for strengthening trust in generic medicines, improving Jan Aushadhi implementation, enhancing regulatory systems, and expanding equitable access — contributing to Universal Health Coverage and improved public health outcomes.

Hyderabad Declaration

Priority areas for action

To translate these commitments into measurable outcomes, we call upon all stakeholders to prioritise action in the following areas:

• Strengthening regulatory capacity and quality assurance systems
• Improving transparency across the pharmaceutical value chain
• Expanding awareness of generic medicines through evidence-based communication
• Promoting rational prescribing and responsible dispensing practices
• Strengthening the implementation and sustainability of the Jan Aushadhi programme
• Improving procurement efficiency and uninterrupted medicine availability
• Investing in institutional capacity building across the healthcare system
• Supporting implementation research and policy evaluation
• Encouraging digital innovation while preserving strong regulatory oversight
• Strengthening partnerships among government, academia, healthcare providers, industry, civil society, and patient organisations

Call to action

Strengthening trust in generic medicines cannot be achieved by any single institution acting alone. Governments, regulatory authorities, healthcare professionals, pharmaceutical manufacturers, pharmacists, academic institutions, researchers, civil society organisations, patient groups, and development partners each have a distinct and complementary role.

We therefore call upon all stakeholders to work collaboratively to transform policy intent into measurable public health outcomes through sustained institutional cooperation, responsible leadership, and continuous implementation learning.

Looking ahead

The Hyderabad Policy Conclave marks not the conclusion of a dialogue, but the beginning of a sustained collaborative effort. The knowledge generated — including this declaration, policy briefs, rapporteur reports, and implementation recommendations — will contribute to the National Implementation Compendium and the Digital Knowledge Repository.

We reaffirm that affordable healthcare is both a public health imperative and a social responsibility. By strengthening trust in generic medicines, reinforcing regulatory systems, improving implementation, and placing patients at the centre of delivery, India can further its leadership in ensuring that quality healthcare is accessible, affordable, and trusted by every citizen.

Way Forward

The conclave demonstrated that India has both the capability and the opportunity to strengthen trust in generic medicines and accelerate access to affordable healthcare. The challenge ahead lies in translating these strengths into consistent implementation and measurable public health outcomes.

No single intervention will be sufficient. Sustainable progress will require coordinated action across policy, regulation, healthcare delivery, industry, academia, civil society, and communities. Trust must be cultivated through transparent institutions, evidence-based decision-making, consistent quality assurance, responsible prescribing, informed patients, and accountable implementation systems.

Implementation learning must become an integral part of public policy. Continuous monitoring, operational research, documentation of good practices, and periodic evaluation are essential. Technology will play an increasing role — digital platforms, data-driven monitoring, artificial intelligence, and modern supply-chain management can strengthen transparency and availability — but must reinforce, not replace, strong institutions and professional accountability.

The conclave should be viewed not as a one-time event, but as the beginning of a sustained national dialogue on implementation excellence in affordable healthcare. Vaaradhi Trust, through Generics for All, in collaboration with SPPG, TISS Hyderabad, remains committed to facilitating continued dialogue, generating implementation evidence, promoting public awareness, and supporting partnerships.

The vision is clear: a healthcare system where affordability is matched by quality, accessibility is reinforced by trust, and policy aspirations are realised through effective implementation. The Hyderabad Policy Conclave has laid the foundation. The responsibility now rests with all stakeholders to transform these deliberations into action and these recommendations into lasting public health impact.